“We believe in a future where biomanufacturing is seamless, scalable, and accessible to all, driving innovation and improving lives.”

Dr. Jason Murphy is a renowned expert with over 25 years of trailblazing experience at industry giants like Moderna, Eli Lilly, and Merck. As a pivotal figure in the development and manufacturing of Moderna’s COVID-19 vaccine, Dr. Murphy led a dynamic, cross-functional team, ensuring the rapid and safe production of this and other groundbreaking therapies.

At Eli Lilly, he spearheaded the Lilly Fermentation Development Technical Center. His leadership extended to the Biotech and Fermented Products Network, where he was instrumental in supporting operations that contributed to nearly half of Elanco’s revenue.

During his 14-year tenure at Merck, Dr. Murphy was a key player in the process development and commercialization of vaccines and biologics.

Dr. Murphy holds a B.S. in Chemical Engineering from the University of California, Berkeley, and both an M.S. and Ph.D. in Chemical Engineering from the University of Houston.

“Strategic partnerships drive progress—our role is to align innovation with execution in real time.”

Matt Krusen brings over a decade of commercial leadership in biomanufacturing, with deep expertise across gene and cell therapy platforms. Before joining Electron Bio, he held senior roles at Aldevron, where he led client development, GMP strategy, and strategic alliances supporting global therapeutic programs in plasmid DNA, mRNA, and viral vector production.

Throughout his career, Matt has worked at the intersection of science and business, helping biopharma partners navigate the complex landscape of manufacturing scale-up, regulatory requirements, and CMC planning.

At Electron Bio, Matt leads business development and strategic partnerships, supporting the company’s digital-first, biomanufacturing-focused platform. His experience across commercial strategy and GMP operations positions him to accelerate client programs and advance the company’s mission to deliver faster, smarter solutions for modern therapeutics.

Matt holds an M.S. in Biochemistry and Integrated Biomedical Science, with a focus in Infectious Disease, from the University of Notre Dame.